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http://dx.doi.org/10.1016/j.kjms.201Abstract Human respiratory syncytial virus (HRSV) infects all age groups and causes bronch-
iolitis, pneumonia, and acute respiratory distress syndrome with a significant mortality rate.
To date, only ribavirin has been used to manage HRSV infection. However, ribavirin is expen-
sive with an only modest effect. Furthermore, ribavirin has several side effects, which means it
has limited clinical benefit. Pueraria lobata Ohwi (P. lobata) is a common ingredient of Ge-
Gen-Tang (Kakkon-to) and Sheng-Ma-Ge-Gen-Tang (Shoma-kakkon-to), which are prescriptions
of Chinese traditional medicine proven to have antiviral activity against HRSV. Therefore, it
was hypothesized that P. lobata might be effective against HRSV. To find a cost-effective ther-
apeutic modality, both human upper (HEp-2) and lower (A549) respiratory tract cell lines were
used to test the hypothesis that P. lobata could inhibit HRSV-induced plaque formation. Results
showed that the water extract of P. lobata was effective (p < 0.0001) against HRSV-inducedof Renal Care, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
J.-S. Chang).
hsiung Medical University. Published by Elsevier Taiwan LLC. All rights reserved.
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652 T.-J. Lin et al.plaque formation. P. lobata was more effective when given prior to viral inoculation
(p < 0.0001) by inhibiting viral attachment (p< 0.0001) and penetration (p< 0.0001). However,
supplementation with P. lobata could not stimulate interferon secretion after HRSV infection.
In conclusion, P. lobata has antiviral activity against HRSV-induced plaque formation in airway
mucosa mainly by inhibiting viral attachment and internalization. Further identification of
effective constituents could contribute to the prevention of HRSV infection.
Copyright ª 2013, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Human respiratory syncytial virus (HRSV) is a common
airway virus that infects patients of all age groups. HRSV is
the leading cause of severe viral bronchiolitis [1] and
pneumonia [2] in infants and children. The annual mortality
rate is 160,000e600,000 deaths worldwide [3]. HRSV is also
a threat to adults older than 65 years and to immunocom-
promised patients by causing pneumonia and exacerbations
of pulmonary diseases [4]. HRSV infection may cause acute
respiratory distress syndrome in healthy adults with a
mortality rate ranging from 40% to 60% [5]. To date, the
only Food and Drug Administration-approved agent to
manage HRSV infection is ribavirin, which has a limited
effect and a marginal clinical benefit [3]. Furthermore,
ribavirin needs to be aerosolized for administration to
manage HRSV infection. However, it is expensive [6] and
has several side effects, such as causing teratogenesis to
healthcare workers [7]. Therefore, safe and cost-effective
anti-HRSV chemoprevention and/or chemotherapies are
urgently needed.
Pueraria lobata Ohwi (P. lobata) has been used for
thousands of years in China to manage fever, diarrhea, and
diabetes [8]. There are several pharmacological activities
to support its modern clinical applications in cerebrovas-
cular diseases, cardiovascular diseases, and hyperlipidemia
[8]. Furthermore, P. lobata has been used as a hangover
and/or alcoholism remedy to treat alcohol-related prob-
lems [9,10]. P. lobata is also a common ingredient of Ge-
Gen-Tang (GGT; Kakkon-to) and Sheng-Ma-Ge-Gen-Tang
(SMGGT; Shoma-kakkon-to), which are prescriptions of
Chinese traditional medicine for airway symptoms. GGT and
SMGGT have been proven to have antiviral activity against
HRSV [11,12]. Therefore, we hypothesized that P. lobata
was one of the active constituents of GGT and SMGGT
against HRSV. However, the only antiviral activity of
P. lobata reported is against EV71 [13]. Therefore, we used
both human upper (human larynx epidermoid carcinoma
cell, HEp-2) and lower (human lung carcinoma cell, A549)
respiratory tract cell lines to test the hypothesis that
P. lobata is effective on HRSV-induced plaque formation.Materials and methods
Preparation of hot water extracts of P. lobata
P. lobata was purchased from herbal shops in Southern
Taiwan. The authenticity had been confirmed at least twicethrough morphological and anatomical identifications by
Dr Ming Hong Yen, Graduate Institute of Natural Products,
Kaohsiung Medical University, Kaohsiung, and by Professor
Den En Shieh, Department of Food Science and Technology,
Tajen University of Technology, Ping-Tung, Taiwan. A
voucher specimen was prepared and deposited at Kaoh-
siung Medical University Herbarium. A hot water extract of
P. lobata was prepared as reported previously [13,14].
Briefly, 100 g of P. lobata were shade-dried and decocted
for 1 hour with 1 L of boiling reverse-osmosis-treated water
three times. The decoctions were mixed, filtered,
concentrated, and lyophilized. The w/w yield of P. lobata
was 9.4%. The extract of P. lobata was dissolved in mini-
mum essential medium (MEM) supplemented with 10% fetal
calf serum (FCS) to the final concentrations of 10 mg/mL,
30 mg/mL, 100 mg/mL, and 300 mg/mL for bioactivity and up
to 3000 mg/mL for cytotoxicity tests prior to the
experiments.
Human cell lines and HRSV
Human upper and lower respiratory tract cell lines, larynx
epidermoid (HEp-2, American Type Culture Collection,
ATCC CCL-23), and lung carcinoma cell lines (A549, ATCC
CCL-185), were used to culture HRSV (Long strain: ATCC VR-
26). Cells were propagated at 37C under 5% CO2 in MEM
supplemented with 10% FCS and antimicrobials. The virus
was propagated on 90% confluent cell monolayer in MEM
with 2% FCS and antimicrobials. Viral titer was determined
and expressed as plaque forming units (pfu)/mL [12]. The
virus was stored at e80C until use.
Cytotoxicity assay
Cytotoxicity of P. lobata on proliferating cells was
assayed by XTT {sodium 30-[1-(phenylamino-carbonyl)-3,4-
tetrazolium]-bis (4-methoxy-6-nitro) benzene sulfonic
acid}-based method according to the manufacturer’s in-
structions (Roche, Mannheim, Germany) [12]. Briefly, 104
cells/well were seeded into 96-well culture plates and
incubated overnight at 37C under 5% CO2. The medium was
removed and different concentrations (10 mg/mL, 30 mg/
mL, 100 mg/mL, 300 mg/mL, 1000 mg/mL, and 3000 mg/mL)
of P. lobata were applied in triplicate. After 3 days of in-
cubation, the cytotoxicity was determined by XTT kit
(Roche, Mannheim, Germany) according to the manufac-
turer’s instructions. The 50% cytotoxic concentration (CC50)
of P. lobata was calculated by the regression analysis of the
doseeresponse curve generated from the data.
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Figure 1. Cytotoxicity assay. Pueraria lobata did not show
any cytotoxicity against host cells up to the concentration of
3000 mg/mL after 3 days’ incubation. Data are presented as
mean  standard deviation of three triplicates.
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Antiviral activity of P. lobata was examined by plaque
reduction assay [12]. Briefly, 105 cells/well were plated in
12-well culture plates at 37C under 5% CO2 for 24 hours and
inoculated with a mixture of 200 pfu/well viruses and
various concentrations of extract of P. lobata at room
temperature for 1 hour. Ribavirin (Sigma-Aldrich, St Louis,
MO, USA) was the positive control. After supplement of
overlay medium (MEM plus 2% FCS in 1% methylcellulose),
they were cultured at 37C under 5% CO2 for 3 days. The
monolayer was then fixed with 10% formalin, stained with
1% crystal violet, and plaques were counted. All experi-
ments were done three times in triplicate. The minimal
concentration required to inhibit 50% cytopathic effect
(IC50) of P. lobata was calculated by the regression analysis
of the doseeresponse curve generated from the data.
Time of addition assay
Antiviral activity of P. lobata was examined at different
time points prior to and after viral inoculation by plaque
reduction assay [12]. Briefly, cells were seeded and incu-
bated for 24 hours as previously described. Various con-
centrations of P. lobata were supplemented at 2 hours or
1 hour prior to viral inoculation, or 1 hour or 2 hours after
viral inoculation. Supernatant was removed prior to the
supplement of overlay medium. Cells were incubated for a
further 72 hours and examined by plaque assay. All exper-
iments were done three times in triplicate.
Attachment assay
Plaque reduction assay was used to evaluate the effect of
P. lobata on viral attachment [12]. Briefly, cells were
seeded and incubated for 48 hours. Cells were prechilled at
4C for 1 hour and the medium was removed. A mixture of
200 pfu/well HRSV was supplemented with various con-
centrations of P. lobata. After incubation at 4C for another
3 hours, the free virus was removed. The cell monolayer
was washed with ice-cold phosphate-buffered saline (PBS)
three times, covered with overlay medium, incubated for
further 72 hours at 37C under 5% CO2, and examined
by plaque assay. All experiments were done twice in
triplicate.
Internalization assay
Effect of P. lobata on viral internalization was evaluated at
20-minute intervals following viral adsorption also by pla-
que reduction assay [12]. Briefly, the cell monolayer was
grown in 12-well culture plates and prechilled at 4C for
1 hour. Cells were infected with 200 pfu/well HRSV and
were incubated at 4C for 3 hours to allow virus binding
without internalization. The virus-containing medium was
replaced with fresh medium containing various concentra-
tions of P. lobata. Cells with various concentrations of
P. lobata were shifted to 37C. At 20-minute, 40-minute, or
60-minute intervals following the 37C shift, acidic PBS (pH
3) was supplemented for 1 minute to inactivate non-
internalized virus and followed by alkaline PBS (pH 11) forneutralization. Then, PBS was replaced by fresh overlay
medium. After incubation at 37C for a further 72 hours,
the cell monolayer was examined by plaque assay. All ex-
periments were done three times in triplicate.
Interferon-b assay
After the antiviral effect assay experiment mentioned
above, the culturemediumwas collected and assayed by the
interferon (IFN)-b enzyme-linked immunosorbent assay
(ELISA) kit (PBL Biomedical Laboratories, Piscataway Town-
ship, NJ, USA) according to the manufacturer’s instructions.
All experiments were done three times in triplicate. The
absorbance at A450 nm was determined with an ELISA reader
(Multiskan EX; Labsystems, Beverley, MA, USA).
Statistical analysis
Results are expressed as mean  standard deviation [15].
Percentage of control (infection rate; %) was calculated
from the plaque counts of P. lobata groups divided by that
of viral control. Data were analyzed with analysis of vari-
ance by JMP 9.0.0 software (SAS, Cary, NC, USA). The Tukey
honestly significant difference test was used to compare all
pairs of groups in the analysis of variance test. A
p value < 0.05 was considered statistically significant.
Results
Cytotoxicity assay
To determine whether P. lobata was toxic to cells, a cyto-
toxicity assay was performed with the XTT assay. P. lobata
did not show any cytotoxicity against HEp-2 and A549 cells up
to a concentration of 3000 mg/mL (Fig. 1). The estimated
CC50 was more than 3000 mg/mL. High CC50 proved its safety.
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Figure 2. Antiviral effect assay. Both Pueraria lobata (A) and ribavirin (B) were dose-dependently (p < 0.0001) effective against
human respiratory syncytial virus as determined by plaque reduction assay after 3 days’ incubation. P. lobata was more effective on
A549 cells than on HEp-2 cells (p< 0.0001). By contrast, ribavirin did not show this difference. Data are presented asmean standard
deviation of three triplicates. *p< 0.05; **p< 0.001; and ***p< 0.0001 were compared to the viral control (0 mg/mL). **** p< 0.05 was
compared between the different cell types at the same concentrations.
654 T.-J. Lin et al.Antiviral effect assay
To determine the anti-HRSV activity, an antiviral effect
assay was performed through the plaque reduction method.
P. lobata and ribavirin were dose-dependently effective
against HRSV in HEp-2 and A549 cells (Fig. 2; p < 0.0001).
P. lobata was more effective on A549 than on HEp-2 cells
(Fig. 2A; p < 0.0001). However, ribavirin did not show this
preference on A549 cells (Fig. 2B). The calculated IC50 of
P. lobata was 258.7 mg/mL in A549 cells and 299.8 mg/mL in
HEp-2 cells.
Time of addition assay
Because P. lobata was effective against HRSV, time of
addition assay was done to find out its working point. The
effect of P. lobata was dose dependent against HRSV on HEp-2 cells
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Figure 3. Time of addition assay. The effect of Pueraria lobata
syncytial virus on HEp-2 (A) and A549 cells (B). This activity was also
when given prior to viral inoculation (p < 0.0001). Data are present
**p < 0.001; and ***p < 0.0001 were compared to the viral controlHEp-2 and A549 cells and was affected by the time of
addition (Fig. 3; p < 0.0001). P. lobata was more effective
on A549 cells, particularly when given prior to viral inocu-
lation (Fig. 3; p < 0.0001). Therefore, P. lobata worked
better as a preventive agent. The calculated IC50 was
233.5 mg/mL (2 hours earlier) in A549 cells.
Attachment assay and internalization assay
P. lobata showed its better effect when given prior to viral
inoculation. Therefore, P. lobata was supposed to work on
viral attachment and/or internalization. The results of
attachment assay confirmed this assumption. P. lobata was
dose-dependently effective against viral attachment
(Fig. 4; p < 0.0001), particularly on A549 cells (p < 0.0001).
The calculated IC50 was 157.9 mg/mL in A549 cells and 255.8
mg/mL in HEp-2 cells. A549 cells
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Figure 4. Attachment assay. of Pueraria lobata was dose-
dependently effective against viral attachment in HEp2 cells
and A549 cells (p < 0.0001), particularly on A549 cells
(p < 0.0001). Data are presented as mean  standard deviation
of two triplicates. *p < 0.05; **p < 0.001; and ***p < 0.0001
were compared to the control group (0 mg/mL).
P. lobata inhibited HRSV 655As for the viral internalization assay, P. lobata was time-
dependently and dose-dependently effective in inhibiting
viral penetration (Fig. 5; p < 0.0001), particularly on A549
cells (p < 0.0001). The effect was similar to that of
attachment assay. The calculated IC50 values were 208.2
mg/mL (60 minutes) in A549 cells, and 299.2 mg/mL (60
minutes) in HEp-2 cells, respectively.IFN-b assay
With regard to the fact that P. lobata was effective against
HRSV and that IFN could be the main cellular mechanismHEp-2 cells
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Figure 5. Internalization assay. Pueraria lobata was time-depend
against viral penetration in HEp-2 cells (A) and A549 cells (B). Data a
*p < 0.05; **p < 0.001; and ***p < 0.0001 were compared to the vagainst viral infection, it was interesting to ascertain
whether the effect of P. lobata was mediated by stimula-
tion of IFN secretion. Results showed that P. lobata dose-
dependently stimulated cells to secrete IFN-b without
HRSV infection. Infection of HRSV also induced IFN-b
secretion in A549 cells (Fig. 6; p < 0.05). However, sup-
plementation with P. lobata after viral inoculation had no
effect on IFN secretion.
Discussion
In this study, P. lobata has for the first time been proven to
inhibit HRSV-induced plaque formation in both HEp-2 cells
and A549 cells. HEp-2 and A549 cells represent upper and
lower respiratory tract mucosal cells, respectively. HRSV
mainly targets the low respiratory tract to result in
morbidity and mortality [16,17]. Therefore, an effective
anti-HRSV agent has to show a better effect on the low
respiratory tract mucosa. Our results fulfilled this character
that P. lobata was effective to protect whole airway mu-
cosa with a better effect on A549 cells (Fig. 2A) to possibly
mitigate the disease severity. An effective antiviral agent
needs to block the set-up of an infection and/or to block
the replication cycle of viruses. Our time of addition assay
showed that P. lobata was more effective when given prior
to viral inoculation by inhibiting viral attachment (Fig. 4)
and penetration (Fig. 5). These results indicate that
P. lobata interferes with the early stages of HRSV infection.
Therefore, P. lobata potentially prevents the set-up of an
infection, rather than blocking the replication cycle of
HRSV. All these results were consistent, thus confirming
their validity.
Ribavirin has been used to treat HRSV infection of the
low respiratory tract in infants and young children [18], in
adult females with HRSV pneumonia-induced acute respi-
ratory distress syndrome [5], and in patients after lung [19],
liver [20], or allogeneic hematopoietic stem cell trans-
plantation [21]. Nevertheless, the efficacy of ribavirin
against HRSV pneumonia in older children and adults has
not been established. Therefore, its effect has been ques-
tioned [22]. It has been shown that 1 mg/mL ribavirin couldA549 cells
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Figure 6. Interferon (IFN)-b assay. Human respiratory syncytial virus infection increased IFN-b secretion in HEp-2 (A) and A549 (B)
cells. P. lobata stimulated HEp-2 (A) and A549 (B) cells to secrete IFN-b only at high concentrations without human respiratory
syncytial virus infection. Data are presented as mean  standard deviation of three triplicates. *p < 0.05; **p < 0.001; and
***p < 0.0001 were compared to the group (0 mg/mL). **** p < 0.05 was compared to the cell control (0 mg/mL without viral
inoculation).
656 T.-J. Lin et al.reduce more than 50% of HRSV-induced plaque formation
with a noticeable decrease of syncytial size at 3 mg/mL
[23]. By contrast, our experiment showed that ribavirin of
3 mg/mL was barely effective and it caused only approxi-
mately 15% reduction of plaque formation at 10 mg/mL
(Fig. 2B). Ribavirin could easily penetrate into HEp-2 and
A549 cells to exert its antiviral effect against HRSV [24].
Compared with previously reported results, our data are
more compatible with the clinical effects. Therefore,
ribavirin is not a good candidate to manage HRSV infection,
particularly for lower respiratory tract infection.
SMGGT and GGT [11,12] are different Chinese traditional
prescriptions. P. lobata is one of the common ingredients of
GGT and SMGGT. P. lobata was effective at the concen-
trations of 30 mg/mL on A549 cells and 100 mg/mL on HEp-2
cells. P. lobata inhibited viral attachment and penetration.
All these results were consistent, thus confirming their
validity. P. lobata showed a similar activity against HRSV as
GGT and SMGGT. These results supported our hypothesis
that P. lobata was one of the active ingredients of SMGGT
and GGT against HRSV. Nevertheless, there are four com-
mon ingredients in GGT and SMGGT: P. lobata; Glycyrrhiza
uralensis [25]; Paeonia lactiflora [26], and Zingiber offici-
nale [24]. All these common ingredients have potent anti-
viral activity against HRSV. Therefore, although P. lobata is
one of the active ingredients, it is not the major component
in these traditional prescriptions.
IFN enhances the cellular resistance against viral infec-
tion [27,28] and this can be the main cellular mechanism
against viral infection [29]. P. lobata stimulated HEp-2 and
A549 cells to secrete IFN-b without HRSV infection (Fig. 6).
However, the stimulatory effect disappeared after viral
challenge (Fig. 6). It has been proposed that viral F protein
can induce the production of IFN-b [30,31]. However, viral
NS1, NS2, and G proteins mediate the evasion of cellular IFN
response for viral advantage [32]. Therefore, improvement
of IFN secretion can be beneficial against HRSV infection.
Nevertheless, P. lobata failed to stimulate interferon
secretion after HRSV infection.In conclusion, P. lobata could possibly be used to pre-
vent HRSV infection mainly by inhibiting viral attachment
and internalization. Further identification of the effective
constituents is necessary to develop the cost-effective
therapeutic modalities against HRSV.References
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